# A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

> **NCT07232407** · PHASE1 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 22 (estimated)

## Conditions studied

- Gastrointestinal Tumors
- Solid Tumors

## Interventions

- **DRUG:** Lutetium [177Lu] BL-ARC001

## Key facts

- **NCT ID:** NCT07232407
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-14
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232407, "A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07232407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*